Somaxon Pharmaceuticals, Inc. Announces Settlement of Silenor Patent Litigation With Mylan Pharmaceuticals, Inc. and Par Pharmaceutical Companies, Inc.

SAN DIEGO, July 17, 2012 (GLOBE NEWSWIRE) -- Somaxon Pharmaceuticals, Inc. (Nasdaq:SOMX), a specialty pharmaceutical company, today announced that it has entered into separate settlement arrangements with Mylan Inc. and its subsidiary, Mylan Pharmaceuticals, Inc. and Par Pharmaceutical Companies, Inc. and its subsidiary Par Pharmaceutical, Inc. to resolve pending patent litigation involving Silenor® 3 mg and 6 mg tablets.